Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
garsorasib + cetuximab beta
- Development stage
- Phase 2
- Lead developer
- InventisBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Garsorasib + cetuximab beta is a combination therapy being investigated for the treatment of KRAS G12C-mutated non-small cell lung cancer (NSCLC). Garsorasib (also known as D-1553 or goselasib) is a potent, selective, and covalent small molecule inhibitor that irreversibly binds to the GDP-bound state of the KRAS G12C mutant protein, locking it in an inactive conformation and preventing downstream oncogenic signaling. Cetuximab beta is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The combination is designed to enhance therapeutic efficacy by simultaneously inhibiting the KRAS G12C mutation and blocking EGFR-mediated bypass signaling pathways, which are common mechanisms of resistance to KRAS G12C monotherapy. This combination is currently being evaluated in clinical trials led by Sun Yat-sen University Cancer Center.
- Other names
- D-1553 + cetuximab betagoselasib + cetuximab beta
02
Targets
EGFR (Epidermal growth factor receptor)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on garsorasib + cetuximab beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on garsorasib + cetuximab beta.